A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Clinical trial NCT05694260 · COMPLETED
Trial details
- NCT number
- NCT05694260
- Sponsor
- Esperion Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-12
- Primary completion
- 2025-06-04
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.